| Literature DB >> 31400263 |
Miriam Dibo1, Eduardo C Battocchio1, Lucas M Dos Santos Souza1, Matheus D Veloso da Silva1, Bruna K Banin-Hirata2, Milena M M Sapla2, Poliana Marinello2, Sérgio P D Rocha1, Lígia C Faccin-Galhardi1.
Abstract
The epidemiological impact of viral diseases, combined with the emergence and reemergence of some viruses, and the difficulties in identifying effective therapies, have encouraged several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy for the treatment of viral diseases is increasing. One of the strategies of immunotherapy is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies, which bind directly to the viral antigen and bring about activation of the immune system. With current advancements in science and technology, several such antibodies are being tested, and some are already approved and are undergoing clinical trials. The present work aims to review the status of mAb development for the treatment of viral diseases. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Immunotherapy; emerging viruses; immunotherapeutics; monoclonal antibodies; treatment; viral diseases.
Mesh：
Substances：
Year: 2019 PMID： 31400263 DOI： 10.2174/1389201020666190809112704
Source DB: PubMed Journal: Curr Pharm Biotechnol ISSN： 1389-2010 Impact factor: 2.837